Patent classifications
A01N63/40
ANTI-VIRAL PAINTS AND COATINGS AND ARTICLES COMPRISING SAME
Disclosed herein are material composition formulated for mitigating activity of a virus on a surface of an article. Methods of preparing such a material composition are also disclosed.
ANTI-VIRAL PAINTS AND COATINGS AND ARTICLES COMPRISING SAME
Disclosed herein are material composition formulated for mitigating activity of a virus on a surface of an article. Methods of preparing such a material composition are also disclosed.
VIRAL ACTIVE AND/OR ANTI-MICROBIAL INKS AND COATINGS
An ink comprises (i) a carrier; (ii) graphene and/or graphene oxide particles dispersed in the carrier; and (iii) a viral active and/or anti-microbial component adhered to the graphene and/or graphene oxide particles.
VIRAL ACTIVE AND/OR ANTI-MICROBIAL INKS AND COATINGS
An ink comprises (i) a carrier; (ii) graphene and/or graphene oxide particles dispersed in the carrier; and (iii) a viral active and/or anti-microbial component adhered to the graphene and/or graphene oxide particles.
ANTI-VIRAL PAINTS AND COATINGS AND ARTICLES COMPRISING SAME
Disclosed herein are material composition formulated for mitigating activity of a virus on a surface of an article. Methods of preparing such a material composition are also disclosed.
ANTI-VIRAL PAINTS AND COATINGS AND ARTICLES COMPRISING SAME
Disclosed herein are material composition formulated for mitigating activity of a virus on a surface of an article. Methods of preparing such a material composition are also disclosed.
CHIMERIC BACTERIOPHAGE LYSIN WITH ACTIVITY AGAINST STAPHYLOCOCCI BACTERIA
The present description relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.
CHIMERIC BACTERIOPHAGE LYSIN WITH ACTIVITY AGAINST STAPHYLOCOCCI BACTERIA
The present description relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.
<i>Escherichia coli</i> bacteriophage Esc-COP-9 and use for inhibiting proliferation of pathogenic <i>Escherichia coli</i> thereof
The present invention relates to a Siphoviridae bacteriophage Esc-COP-9 (Accession number: KCTC 13131BP) isolated from nature, which has the ability to specifically kill Escherichia coli and which includes a genome expressed by SEQ. ID. NO: 1, and to a method of preventing and treating a pathogenic Escherichia coli infection using a composition including the same as an active ingredient.
<i>Escherichia coli</i> bacteriophage Esc-COP-9 and use for inhibiting proliferation of pathogenic <i>Escherichia coli</i> thereof
The present invention relates to a Siphoviridae bacteriophage Esc-COP-9 (Accession number: KCTC 13131BP) isolated from nature, which has the ability to specifically kill Escherichia coli and which includes a genome expressed by SEQ. ID. NO: 1, and to a method of preventing and treating a pathogenic Escherichia coli infection using a composition including the same as an active ingredient.